Greater Poland Cancer Center

What Greater Poland Cancer Center does

Greater Poland Cancer Center (Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie) is a publicly owned oncology hospital founded in 1953 in Poznań, Poland, and operated as a self-contained public healthcare institution (samodzielny publiczny zakład opieki zdrowotnej) under the Marshal Office of the Wielkopolskie Region. It is the only facility in the voivodeship delivering the full combined modality of surgical, radiotherapy, and chemotherapy cancer treatment, operating the main Poznań campus plus branches in Kalisz and Piła and serving a catchment population of approximately 3.5 million. The center employs 501-1000 staff and runs a high-capex clinical technology stack including CyberKnife, Tomotherapy, Varian linear accelerators, Siemens Somatom Confidence RT PRO CT, PET-CT, MRI, nuclear medicine, and brachytherapy, plus an in-house gene therapy laboratory developing cancer vaccines for melanoma, renal cell carcinoma, and glioma.

The service portfolio spans diagnostics, imaging, nuclear medicine, surgical and non-surgical oncology, radiotherapy, chemotherapy, and translational research, supported by an academic affiliation with Poznan University of Medical Sciences and memberships in OECI, the Polish Hospital Federation, and ESTRO. Revenue mechanics rely primarily on National Health Fund (NFZ) reimbursement for publicly insured patients, supplemented by regional and central government subsidies, EU and National Recovery Plan (KPO) capital grants, and out-of-pocket fees from private patients. A 61 million PLN modernization program (announced June 2026) and the addition of three new operating rooms with a robotic surgery program (announced April 2026) indicate active capacity expansion across both hardware and service line.

Digitization efforts include online patient registration (eRejestracja) and online results delivery (eWyniki), patient-facing tools that point to incremental ecosystem buildout rather than a wholesale digital pivot. As a public-sector institution, the center is not for-profit, is not PE-/VC-investable in the conventional sense, and is best framed for an M&A audience as a strategic public-asset comparable — useful for benchmarking regional oncology infrastructure, capex flows, and accreditation dynamics in Central European healthcare.

Name

Greater Poland Cancer Center

Legal name

Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie

Website

https://wco.pl

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Greater Poland Cancer Center is a publicly owned oncology hospital in Poznań, Poland, founded in 1953 and the only facility in the Wielkopolskie Voivodeship offering combined surgical, radiotherapy, and chemotherapy cancer treatment to a regional population of approximately 3.5 million.

Ownership category

akta.pro rank

Product category

Oncology Hospital / Cancer Treatment Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (6223)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

Keywords

• Cancer treatment services
• Radiation therapy
• Oncology hospital
• Chemotherapy services
• Cancer diagnostics

Headquarters

HQ city

Poznan

HQ country

Poland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others

Revenue model

1. National Health Fund (NFZ) Reimbursement: As a public oncology hospital (samodzielny publiczny zakład opieki zdrowotnej), WCO receives the majority of its funding through contracts with the National Health Fund (Narodowy Fundusz Zdrowia, NFZ), Poland's public health insurer. Services covered include radiotherapy, chemotherapy, immunotherapy, surgery, diagnostics, and preventive programs, billed on a procedure and case-mix basis under Poland's public healthcare framework.
2. Government Budget Subsidies and EU Grants: The center receives direct funding from the Wielkopolskie Voivodeship government (Samorząd Województwa Wielkopolskiego) and national state budget allocations. It also implements projects funded by the Wielkopolski Regionalny Program Operacyjny (WRPO / European Regional Development Fund) and the KPO (Krajowy Plan Odbudowy / National Recovery Plan), as evidenced by a reported 61 million PLN investment in modern diagnostic and therapeutic equipment, infrastructure development, and digitalization.
3. Private Patient Fees: The center publishes a medical services price list (cennik usług medycznych) indicating that fee-for-service private treatment is available for patients not covered under public insurance or seeking services outside NFZ contracts.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Greater Poland Cancer Center delivers integrated cancer diagnosis and treatment, combining oncological surgery, radiotherapy (CyberKnife, Tomotherapy, Varian linear accelerators, brachytherapy), chemotherapy, immunotherapy, nuclear medicine, and advanced diagnostic imaging (PET-CT, MRI, mammography) at its Poznań campus and radiotherapy branches in Kalisz and Piła. It also runs cancer gene therapy and immunology research laboratories and participates in national cancer screening programs.

Product overview

Greater Poland Cancer Center (Wielkopolskie Centrum Onkologii) is a comprehensive oncology hospital offering integrated cancer care services. The center provides a full range of treatment modalities including oncological surgery, radiotherapy (with advanced techniques such as Tomotherapy, CyberKnife, and Brachytherapy), chemotherapy, and immunotherapy. Diagnostic services include advanced imaging (MRI, CT, PET-CT, mammography, ultrasound), nuclear medicine, and flow cytometry. The center also operates specialized departments for gynecological oncology, a gene therapy laboratory, and cancer immunology research. Digital services include e-Registration for online appointment booking. The facility operates as a single integrated hospital with multiple specialized departments and two branch locations in Kalisz and Piła.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncological Surgery
• Radiotherapy
• Tomotherapy
• CyberKnife Stereotactic Radiosurgery
• Brachytherapy
• Chemotherapy
• Immunotherapy and Immuno-Oncology
• Diagnostic Imaging
• Nuclear Medicine
• Gynecological Oncology
• Hyperthermia
• Flow Cytometry and Laboratory Diagnostics
• Cancer Screening and Prevention Programs
• e-Registration (eRejestracja)
• Gene Therapy and Cancer Immunology Research

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Five partnerships are on record, tiered core and major.

• OECI (Organisation of European Cancer Institutes)coreStrategic or Co-development PartnerWCO is an active member of OECI, a European network of cancer institutes. Membership provides access to benchmarking, best practice exchange, European research collaborations, and certification standards for oncology care quality. WCO holds an OECI membership certificate (2026).
• Polish Hospital Federation (Polska Federacja Szpitali)coreStrategic or Co-development PartnerWCO is a member of the Polish Hospital Federation (PFSZ), an organization representing and advocating for public and private hospitals in Poland. Membership provides institutional representation, policy influence, and peer network access.
• ESTRO (European Society for Radiotherapy & Oncology)majorStrategic or Co-development PartnerWCO maintains an active association with ESTRO, the leading European society for radiotherapy and oncology. The center's radiotherapy staff participate in ESTRO activities, continuing education, and research programs. An ESTRO accreditation/affiliation image is displayed on WCO's website.
• Poznan University of Medical Sciences (Uniwersytet Medyczny w Poznaniu)coreStrategic or Co-development PartnerThe Clinic of Head, Neck and Laryngological Oncology operates at WCO on the basis of the University's department, enabling joint clinical care, academic research, teaching, and the training of medical students and residents. This academic partnership supports WCO's scientific and educational mission.
• Wielkopolskie Voivodeship Government (Samorząd Województwa Wielkopolskiego)coreOthersThe regional government of the Wielkopolskie Voivodeship is WCO's founding and governing authority. It provides budget support, approves strategic decisions, and co-funded a 61 million PLN investment in WCO's modernization. WCO operates as a 'samodzielny publiczny zakład opieki zdrowotnej' under the voivodeship's authority.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Others

• Accuray (CyberKnife / Tomotherapy manufacturer): Manufacturer of the CyberKnife robotic radiosurgery and Tomotherapy systems installed at WCO. As critical infrastructure suppliers, the relationship with the center is a direct technology and service dependency relevant for benchmarking peer-equivalent specialty centers.
• Varian Medical Systems (now Siemens Healthineers / Varian): Leading global supplier of radiotherapy equipment including the linear accelerators in use at WCO. As the primary technology vendor across WCO's radiotherapy platform, it is the most direct supplier/enabler relationship for the center's core oncology treatment capabilities.

Direct peers

• Maria Skłodowska-Curie Specialist Hospital (Krakow Oncology Center) / Oddział Onkologiczny Szpitala im. Skłodowskiej-Curie: Regional oncology referral hospital in Kraków offering surgical, radiotherapy, and chemotherapy services under NFZ contracts. Comparable in service breadth and public-hospital model to WCO.
• Holy Cross Cancer Center (Świętokrzyskie Centrum Onkologii), Kielce: Public voivodeship-level oncology hospital in Kielce delivering surgical oncology, radiotherapy, and chemotherapy to Świętokrzyskie region. Functionally comparable to WCO in scale, services, and NFZ funding model.
• Kuyavian-Pomeranian Pulmonology and Oncology Center (Kujawsko-Pomorskie Centrum Pulmonologii i Onkologii), Bydgoszcz: Multi-specialty regional hospital in Bydgoszcz combining pulmonology and oncology services with surgical and radiotherapy capabilities, serving a neighboring voivodeship under the same NFZ framework as WCO.
• West Pomeranian Oncology Center (Zachodniopomorskie Centrum Onkologii), Szczecin: Specialist oncology hospital serving Zachodniopomorskie Voivodeship with integrated surgical, radiotherapy, and systemic therapy services under NFZ reimbursement. Same public-specialty-hospital category and regulatory setting as Greater Poland Cancer Center.
• Lower Silesian Cancer Center (Dolnośląskie Centrum Onkologii): Regional oncology center in Wrocław serving Dolnośląskie Voivodeship, providing combined surgical, radiotherapy, and systemic therapy services under the same NFZ/public-hospital structure as WCO. Comparable scope, technology stack, and governance model make it the most direct regional peer.
• Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Warsaw: Poland's largest and oldest national cancer institute, also bearing the Skłodowska-Curie name. Operates a comprehensive oncology hospital with surgical, radiotherapy, chemotherapy, and research programs across two Warsaw-area sites, making it the closest functional peer to WCO at the national level.
• Lublin Oncology Center (Centrum Onkologii Ziemi Lubelskiej): Specialist public oncology hospital serving Lubelskie Voivodeship with surgical, radiotherapy, and systemic therapy services. Comparable regional oncology hospital scale and NFZ dependency to Greater Poland Cancer Center.

Broad incumbents

• European Institute of Oncology (IEO), Milan: Large, internationally recognized private-non-profit oncology hospital and research center in Italy. Comparable comprehensive oncology hospital model (surgery, radiotherapy, systemic therapy, screening, research) but at substantially larger scale, providing a benchmark for what a mature specialty oncology hospital can become.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/pages/Wielkopolskie-Centrum-Onkologii/178602148863816

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greater Poland Cancer Center